Publications by authors named "Arie Zask"

Claim this Profile
D
Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening.
Hengrui Liu, Arie Zask, Farhad Forouhar, Sho Iketani, Alana Williams

Nat Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.
Michael E Stokes, Alessandro Vasciaveo, Jonnell Candice Small, Arie Zask, Eduard Reznik

Cell Chem Biol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinases Controlling Stability of the Oncogenic MYCN Protein.
Nailah Smith, Eduard Reznik, Brygida Bisikirska, Vasiliki Polychronidou, Qian Wang, Arie Zask

ACS Med Chem Lett· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
Clara Reglero, Chelsea L Dieck, Arie Zask, Farhad Forouhar, Anouchka P Laurent

Cancer Discov· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19.
Hengrui Liu, Sho Iketani, Arie Zask, Nisha Khanizeman, Eva Bednarova

Nat Commun· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reflections on the intriguing occurrence of some recently isolated natural products as racemates and scalemic mixtures.
Arie Zask, George A Ellestad

Chirality· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
Samuel J Resnick, Sho Iketani, Seo Jung Hong, Arie Zask, Hengrui Liu

J Virol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Arie Zask

Nat Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Arie Zask

Nat Commun· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
Sho Iketani, Farhad Forouhar, Hengrui Liu, Seo Jung Hong, Fang-Yu Lin, Arie Zask

bioRxiv· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A simplified cell-based assay to identify coronavirus 3CL protease inhibitors.
Samuel J Resnick, Sho Iketani, Seo Jung Hong, Arie Zask, Hengrui Liu

bioRxiv· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The enduring legacy of Koji Nakanishi's research on bioorganic chemistry and natural products. Part 1: Isolation, structure determination and mode of action.
George Ellestad, Arie Zask, Nina Berova

Chirality· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of MAP4 Kinase Inhibitors as Motor Neuron-Protecting Agents.
Pieter H Bos, Emily R Lowry, Jonathon Costa, Sebastian Thams, Alejandro Garcia-Diaz, Arie Zask

Cell Chem Biol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomimetic syntheses of racemic natural products.
Arie Zask, George Ellestad

Chirality· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multivalent Small-Molecule Pan-RAS Inhibitors.
Matthew E Welsch, Anna Kaplan, Jennifer M Chambers, Michael E Stokes, Pieter H Bos, Arie Zask

Cell· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Jianchang Qian, Yaqing Chen, Tao Meng, Lanping Ma, Lanfang Meng, Arie Zask

Oncotarget· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent Advances in Stereoselective Drug Targeting.
Arie Zask, George A Ellestad

Chirality· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biological stereoselectivity of atropisomeric natural products and drugs.
Arie Zask, John Murphy, George A Ellestad

Chirality· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of antioxidants for prevention of age-related macular degeneration.
Dharati Joshi, James Field, John Murphy, Mohammed Abdelrahim, Heike Schönherr, Arie Zask

J Nat Prod· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the discovery of small-molecule ATP competitive mTOR inhibitors: a patent review.
Arie Zask, Jeroen C Verheijen, David J Richard

Expert Opin Ther Pat· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in the development of selective, ATP-competitive inhibitors of mTOR.
David J Richard, Jeroen C Verheijen, Arie Zask

Curr Opin Drug Discov Devel· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: optimization of human microsomal stability.
Jeroen C Verheijen, David J Richard, Kevin Curran, Joshua Kaplan, Ker Yu, Arie Zask

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha.
David J Richard, Jeroen C Verheijen, Ker Yu, Arie Zask

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-ureidophenyltriazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors.
Arie Zask, Jeroen C Verheijen, David J Richard, Joshua Kaplan, Kevin Curran

Bioorg Med Chem Lett· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absolute configurations of tubulin inhibitors taltobulin (HTI-286) and HTI-042 characterized by X-ray diffraction analysis and NMR studies.
Chuansheng Niu, Douglas M Ho, Robert Thomas Williamson, Arie Zask, Semiramis Ayral-Kaloustian

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis